23 Jul, 2026
According to Straits Research, the global organ on chip market size was valued at $174.95 million in 2025 and is projected to grow from $216.88 million in 2026 to $1,223.70 million by 2034, registering a CAGR of 24.15% during the forecast period 2026–2034. North America dominated the organ on chip market with a 50.94% market share in 2025.
A key growth driver for the organ-on-chip market is the increasing demand from pharmaceutical companies to replace or supplement animal models with human microphysiological systems. Companies such as Emulate report that nearly 90% of drugs that pass preclinical animal testing fail in human trials, highlighting the need for more predictive models. Advanced Organ-on-Chip platforms, such as Emulate’s high-throughput systems, allow researchers to run dozens of human organ simulations simultaneously, reducing time and cost for drug screening while improving predictive accuracy. This capability accelerates adoption in pharma R&D pipelines and positions Organ-on-Chip technology as an essential tool for safer and faster drug development.
However, the market faces challenges due to high technological complexity, manufacturing costs, and the early stage of regulatory acceptance. Producing Organ-on-Chip devices requires microfluidics, 3D tissue cultures, and integrated sensors, making standardization and scalability difficult. Additionally, partnerships between firms like MIMETAS and large pharmaceutical companies, adoption remains limited to niche applications, and commercial costs per assay remain significantly higher than traditional preclinical models.
On the other hand, applications into multi-organ systems and AI-driven disease modeling represent significant opportunities for market. Leading companies are developing chips that model complex human physiology, including neuroinflammation, tumor microenvironments, and blood-brain-barrier interactions. These innovations allow personalized drug testing and open avenues in oncology, CNS disorders, and immunotherapy, as well as potential applications in cosmetics and chemical safety testing.
North America: Market Dominance Led by Increasing Integration of Organ om Chip Platforms and Growing Investments in AI-enabled Biological Modeling
The North America organ on chip market accounted for the largest regional share of 50.94% in 2025, driven by increasing integration of organ on chip platforms into pharmaceutical decision-making workflows and translational research programs. The region benefits from strong regulatory support for New Approach Methodologies (NAMs), extensive biopharmaceutical R&D activity, and established microphysiological systems expertise. For example, the U.S. FDA's ongoing initiatives supporting human-relevant testing methods are accelerating demand for organ on chip technologies across drug development and safety assessment applications.
Asia Pacific: Fastest Growth Driven by Increasing Support for Non-animal Testing Technologies and Growing Investments in Domestic Biopharmaceutical Innovation
The Asia Pacific organ on chip market is expected to grow at a CAGR of 24.18% during the forecast period, showcasing fastest regional growth. This growth is attributed to region's expanding microfabrication and semiconductor manufacturing ecosystem, which supports large-scale production of advanced microfluidic devices. Governments are also increasing support for non-animal testing technologies. For example, in 2025, Japan and South Korea expanded national initiatives promoting advanced biomedical engineering and next-generation drug evaluation platforms, strengthening demand for organ on chip technologies.
sales@straitsresearch.com